Experimental gene therapy of human colon cancer

R. J. Bold, R. E. Warren, J. Ishizuka, Y. S. Cho-Chung, C. M. Townsend, J. C. Thompson, R. J. Joehl, E. D. Whitman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. Gastrin regulates growth of human colon cancer cells by activation of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA). Gastrin and 8-Br-cAMP, a membrane-permeable cAMP analog, inhibit growth of HCT116 cells; both stimulate growth of LoVo cells. This dual effect on growth may be explained by relative amounts of the regulatory subunit (R(Iα) or R(IIβ) of PKA within the cancer cells. Antisense oligodeoxynucleotides (ASO) to either R(Iα) or R(IIβ) inhibit protein translation of the target mRNA by sequence-specific binding; subsequently, cellular PKA content and the cAMP-mediated growth may be altered. We determined whether ASO to either the R(Iα) or R(IIβ) subunit altered the cAMP-mediated growth of HCT116 and LoVo human colon cancer cells. Methods. HCT116 cells were treated with R(IIβ) ASO (15 μmol/L, 4 days) and then treated with 8-Br-cAMP (25 μmol/L); tritiated thymidine incorporation was measured after 24 hours, and the cell number was determined on alternate days. Protein and mRNA levels of the R(IIβ) subunit were determined by Western and Northern blotting, respectively. Similar studies with an ASO against the R(Iα) subunit were performed on LoVo cells. Results. R(IIβ) ASO reversed the cAMP-mediated inhibition of growth of HCT116 cells, and R(IIβ) ASO decreased the protein level of the R(IIβ) subunit. R(IIβ) ASO did not alter the basal growth of HCT116 cells. R(Iα) ASO reversed the cAMP- mediated stimulation of growth of LoVo cells. Conclusions. The regulatory subunits of PKA are potential targets to alter growth of human colon cancer cells. Gene therapy directed to alter specific steps in signal transduction pathways may provide new therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)189-196
Number of pages8
JournalSurgery
Volume116
Issue number2
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Investigational Therapies
Genetic Therapy
Colonic Neoplasms
Oligodeoxyribonucleotides
Cyclic AMP
HCT116 Cells
Growth
Cyclic AMP-Dependent Protein Kinases
Gastrins
Messenger RNA
Protein Biosynthesis
Northern Blotting
Thymidine
Signal Transduction
Proteins
Cell Count
Western Blotting

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Bold, R. J., Warren, R. E., Ishizuka, J., Cho-Chung, Y. S., Townsend, C. M., Thompson, J. C., ... Whitman, E. D. (1994). Experimental gene therapy of human colon cancer. Surgery, 116(2), 189-196.
Bold, R. J. ; Warren, R. E. ; Ishizuka, J. ; Cho-Chung, Y. S. ; Townsend, C. M. ; Thompson, J. C. ; Joehl, R. J. ; Whitman, E. D. / Experimental gene therapy of human colon cancer. In: Surgery. 1994 ; Vol. 116, No. 2. pp. 189-196.
@article{1e0a2b26bce04fa69a35aec62679087e,
title = "Experimental gene therapy of human colon cancer",
abstract = "Background. Gastrin regulates growth of human colon cancer cells by activation of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA). Gastrin and 8-Br-cAMP, a membrane-permeable cAMP analog, inhibit growth of HCT116 cells; both stimulate growth of LoVo cells. This dual effect on growth may be explained by relative amounts of the regulatory subunit (R(Iα) or R(IIβ) of PKA within the cancer cells. Antisense oligodeoxynucleotides (ASO) to either R(Iα) or R(IIβ) inhibit protein translation of the target mRNA by sequence-specific binding; subsequently, cellular PKA content and the cAMP-mediated growth may be altered. We determined whether ASO to either the R(Iα) or R(IIβ) subunit altered the cAMP-mediated growth of HCT116 and LoVo human colon cancer cells. Methods. HCT116 cells were treated with R(IIβ) ASO (15 μmol/L, 4 days) and then treated with 8-Br-cAMP (25 μmol/L); tritiated thymidine incorporation was measured after 24 hours, and the cell number was determined on alternate days. Protein and mRNA levels of the R(IIβ) subunit were determined by Western and Northern blotting, respectively. Similar studies with an ASO against the R(Iα) subunit were performed on LoVo cells. Results. R(IIβ) ASO reversed the cAMP-mediated inhibition of growth of HCT116 cells, and R(IIβ) ASO decreased the protein level of the R(IIβ) subunit. R(IIβ) ASO did not alter the basal growth of HCT116 cells. R(Iα) ASO reversed the cAMP- mediated stimulation of growth of LoVo cells. Conclusions. The regulatory subunits of PKA are potential targets to alter growth of human colon cancer cells. Gene therapy directed to alter specific steps in signal transduction pathways may provide new therapeutic strategies.",
author = "Bold, {R. J.} and Warren, {R. E.} and J. Ishizuka and Cho-Chung, {Y. S.} and Townsend, {C. M.} and Thompson, {J. C.} and Joehl, {R. J.} and Whitman, {E. D.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "116",
pages = "189--196",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

Bold, RJ, Warren, RE, Ishizuka, J, Cho-Chung, YS, Townsend, CM, Thompson, JC, Joehl, RJ & Whitman, ED 1994, 'Experimental gene therapy of human colon cancer', Surgery, vol. 116, no. 2, pp. 189-196.

Experimental gene therapy of human colon cancer. / Bold, R. J.; Warren, R. E.; Ishizuka, J.; Cho-Chung, Y. S.; Townsend, C. M.; Thompson, J. C.; Joehl, R. J.; Whitman, E. D.

In: Surgery, Vol. 116, No. 2, 01.01.1994, p. 189-196.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Experimental gene therapy of human colon cancer

AU - Bold, R. J.

AU - Warren, R. E.

AU - Ishizuka, J.

AU - Cho-Chung, Y. S.

AU - Townsend, C. M.

AU - Thompson, J. C.

AU - Joehl, R. J.

AU - Whitman, E. D.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background. Gastrin regulates growth of human colon cancer cells by activation of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA). Gastrin and 8-Br-cAMP, a membrane-permeable cAMP analog, inhibit growth of HCT116 cells; both stimulate growth of LoVo cells. This dual effect on growth may be explained by relative amounts of the regulatory subunit (R(Iα) or R(IIβ) of PKA within the cancer cells. Antisense oligodeoxynucleotides (ASO) to either R(Iα) or R(IIβ) inhibit protein translation of the target mRNA by sequence-specific binding; subsequently, cellular PKA content and the cAMP-mediated growth may be altered. We determined whether ASO to either the R(Iα) or R(IIβ) subunit altered the cAMP-mediated growth of HCT116 and LoVo human colon cancer cells. Methods. HCT116 cells were treated with R(IIβ) ASO (15 μmol/L, 4 days) and then treated with 8-Br-cAMP (25 μmol/L); tritiated thymidine incorporation was measured after 24 hours, and the cell number was determined on alternate days. Protein and mRNA levels of the R(IIβ) subunit were determined by Western and Northern blotting, respectively. Similar studies with an ASO against the R(Iα) subunit were performed on LoVo cells. Results. R(IIβ) ASO reversed the cAMP-mediated inhibition of growth of HCT116 cells, and R(IIβ) ASO decreased the protein level of the R(IIβ) subunit. R(IIβ) ASO did not alter the basal growth of HCT116 cells. R(Iα) ASO reversed the cAMP- mediated stimulation of growth of LoVo cells. Conclusions. The regulatory subunits of PKA are potential targets to alter growth of human colon cancer cells. Gene therapy directed to alter specific steps in signal transduction pathways may provide new therapeutic strategies.

AB - Background. Gastrin regulates growth of human colon cancer cells by activation of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA). Gastrin and 8-Br-cAMP, a membrane-permeable cAMP analog, inhibit growth of HCT116 cells; both stimulate growth of LoVo cells. This dual effect on growth may be explained by relative amounts of the regulatory subunit (R(Iα) or R(IIβ) of PKA within the cancer cells. Antisense oligodeoxynucleotides (ASO) to either R(Iα) or R(IIβ) inhibit protein translation of the target mRNA by sequence-specific binding; subsequently, cellular PKA content and the cAMP-mediated growth may be altered. We determined whether ASO to either the R(Iα) or R(IIβ) subunit altered the cAMP-mediated growth of HCT116 and LoVo human colon cancer cells. Methods. HCT116 cells were treated with R(IIβ) ASO (15 μmol/L, 4 days) and then treated with 8-Br-cAMP (25 μmol/L); tritiated thymidine incorporation was measured after 24 hours, and the cell number was determined on alternate days. Protein and mRNA levels of the R(IIβ) subunit were determined by Western and Northern blotting, respectively. Similar studies with an ASO against the R(Iα) subunit were performed on LoVo cells. Results. R(IIβ) ASO reversed the cAMP-mediated inhibition of growth of HCT116 cells, and R(IIβ) ASO decreased the protein level of the R(IIβ) subunit. R(IIβ) ASO did not alter the basal growth of HCT116 cells. R(Iα) ASO reversed the cAMP- mediated stimulation of growth of LoVo cells. Conclusions. The regulatory subunits of PKA are potential targets to alter growth of human colon cancer cells. Gene therapy directed to alter specific steps in signal transduction pathways may provide new therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=0028067819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028067819&partnerID=8YFLogxK

M3 - Article

C2 - 8047985

AN - SCOPUS:0028067819

VL - 116

SP - 189

EP - 196

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -

Bold RJ, Warren RE, Ishizuka J, Cho-Chung YS, Townsend CM, Thompson JC et al. Experimental gene therapy of human colon cancer. Surgery. 1994 Jan 1;116(2):189-196.